FDA approves GlaxoSmithKline’s anaemia drug Promacta
In order to increase production of blood cells, the once-daily use of an oral thrombopoietin (TPO) receptor agonist promacta helps to induce proliferation and differentiation of bone marrow
In order to increase production of blood cells, the once-daily use of an oral thrombopoietin (TPO) receptor agonist promacta helps to induce proliferation and differentiation of bone marrow
Aripiprazole lauroxil is an investigational, new, once-monthly, long-acting injectable atypical antipsychotic. The NDA is based on the positive results from the randomized, multicenter, double-blind, placebo-controlled, phase III trial
PD-L1 (SP142) rabbit monoclonal antibody is for research use only (RUO) and has been developed for Roche/Genentech’s anti-PD-L1 (MPDL3280A) immunotherapy development program as well as in research of
GBM is the most common and most aggressive malignant primary brain tumor in humans. Insys Therapeutics president and chief executive officer Michael Babich said the company is happy
Both the firms have not disclosed financial details of the deal, under which Eurolab has agreed to specific annual commercial goals for Brinavess. Cardiome chief commercial officer Karim
Covagen’s lead product COVA 322, a bispecific anti-tumor necrosis factor (TNF)-alpha/anti-interleukin (IL)-17A FynomAb, is currently in a Phase Ib trial for psoriasis. COVA 322 is also said to
In October 2013, Zorvolex was approved by the FDA to treat mild to moderate acute pain in adults. The prescription-based Zorvolex is the first FDA-approved low dose NSAID
About 25% and possibly up to 50% of deceased-donor kidney transplant cases are affected by DGF, an early and serious complication of organ transplantation. DGF is characterized by
Triumeq is the company’s first dolutegravir-based fixed-dose combination (FDC) which provides HIV patients the option of a single-pill regimen that combines the integrase strand transfer inhibitor (INSTI) dolutegravir,
A decision from the European Commission (EC) regarding the approval of ceftolozane/tazobactam is expected during the second half of 2015 The marketing application is based on positive data